Social functioning violation in patients with paranoid schizophrenia and concomitant somatic and neurologic pathology

Authors

  • Valerii Pidkorytov State Institution "Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine" Ak. Pavlova str., 46 , Kharkiv, Ukraine, 61068, Ukraine
  • Natalia Baibarak State Institution "Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine" Ak. Pavlova str., 46 , Kharkiv, Ukraine, 61068, Ukraine

DOI:

https://doi.org/10.15587/2519-4798.2017.100553

Keywords:

paranoidal schizophrenia, stress resistance, quality of life level dynamics, somatic and neurological pathology, pharmacotherapy

Abstract

The aim was to determine the features of social functioning violation in patients with paranoid schizophrenia and concomitant somatic and neurologic disorders under the influence of neuroleptic treatment and to estimate  psychopharmacotherapy efficiency. It is known that patients with schizophrenia often suffer from concomitant somatic pathology. Schizophrenia course, negative symptoms and cognitive disorders may prevent timely treatment and mental health care for patients with paranoid schizophrenia and concomitant somatic and neurologic disorders.

Methods. According to the specially designed criteria, the main group with paranoid schizophrenia diagnosis  (F 20,0) having somatic and neurologic disorders was determined according to the ICD-10 criteria.

Results. On the basis of the obtained results analysis, it should be mentioned, that patients with paranoid schizophrenia and concomitant somatic and neurologic pathology will probably have poor physical and mental health. Thus, stressful events in life of patients with paranoid schizophrenia worsens somatic health and reduces adaptive potential, which in turn affects all areas of personal communication and general quality of life.

Conclusion. The features of the concomitant somatic and neurologic pathology influence on social activity and quality of life of patients with paranoidal schizophrenia before and after treatment

Author Biographies

Valerii Pidkorytov, State Institution "Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine" Ak. Pavlova str., 46 , Kharkiv, Ukraine, 61068

Doctor of medical sciences, professor

Chief of the Department of Clinical, Social and Pediatric Psychiatry

Natalia Baibarak, State Institution "Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine" Ak. Pavlova str., 46 , Kharkiv, Ukraine, 61068

Senior researcher, PhD

Department of Clinical, Social and Pediatric Psychiatry

References

  1. Drobizhev, M. Yu. (2000). Nosogenic (psychogenic) reactions in somatic diseases. Moscow, 38.
  2. Bushe, C. J., Taylor, M., Haukka, J. (2010). Review: Mortality in schizophrenia: a measurable clinical endpoint. Journal of Psychopharmacology, 24 (4), 17–25. doi: 10.1177/1359786810382468
  3. Dinan, T. G. (2004). Stress and the genesis of diabetes mellitus in schizophrenia. The British Journal of Psychiatry, 184 (47), s72–s75. doi: 10.1192/bjp.184.47.s72
  4. Herold, R. (2012). The long-term treatment of schizophrenia. Orvosi Hetilap, 153 (26), 1007–1012. doi: 10.1556/oh.2012.29416
  5. Nasrallah, H. A., Meyer, J. M., Goff, D. C., McEvoy, J. P., Davis, S. M., Stroup, T. S., Lieberman, J. A. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research, 86 (1-3), 15–22. doi: 10.1016/j.schres.2006.06.026
  6. Insel, T. R., Scolnick, E. M. (2006). Cure therapeutics and strategic prevention: raising the bar for mental health research. Molecular Psychiatry, 11 (1), 11–17. doi: 10.1038/sj.mp.4001777
  7. Neznanov, H. G., Martynikhin, I. A., Sokolyan, N. A., Tanyanskii, D. A. (2009). The frequency and nature of metabolic disorders in patients with schizophrenia. Obozr. Psychiatrist and honey. Psychol. them. V. M. Bechterew, 2, 17–20.
  8. Vasyuk, Yu. A., Dovzhenko, T. V., Shkolnik, E. L. (2007). Peculiarities of the pathogenetic relationship between depression and cardiovascular diseases. Psih, ra-va in general medicine, 2 (1), 14–19.
  9. Brown, S., Birtwistle, J., Roe, L., Thompson, C. (1999). The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29 (3), 697–701. doi: 10.1017/s0033291798008186
  10. Nuller, Yu. L., Tsirkin, S. Yu. (Eds.) (1994). International Classification of Diseases: (10th revision). (1994) Classification of mental and behavioral disorders: Clinical descriptions and guidelines for diagnostics. Saint-Petersburg: AFIS, 302.
  11. Novik, A. A., Ionova, T. I. (2007). Guide to the study of the quality of life in medicine. Moscow: ZAO OLMA Media Group, 320.
  12. Kapponi, V., Novaka, T. (1994). Self psychologist. Saint-Petersburg: Peter, 350.
  13. Smashna, O. Ye. (2011). Influence of concomitant somatic pathology on estimation of quality of living by patients with paranoid form of schizophrenia. Journal Ukrainian psychoneurology, 19 (3 (68)), 70–73.

Downloads

Published

2017-04-29

How to Cite

Pidkorytov, V., & Baibarak, N. (2017). Social functioning violation in patients with paranoid schizophrenia and concomitant somatic and neurologic pathology. ScienceRise: Medical Science, (4 (12), 46–50. https://doi.org/10.15587/2519-4798.2017.100553

Issue

No. 4 (12) (2017)

Section

Medical Science

License

Copyright (c) 2017 Valerii Pidkorytov, Natalia Baibarak

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.